Episode 21. Newly Diagnosed Mantle Cell Lymphoma
Blood Cancer Talks
The Effect of Bena Mustin on PFS and Overall Survival
FDA recently requested manufacturer to withdraw a brute-nebs mantles of lymphoma and marginal zol lymphoma indication. So, obviously, you're not based in the US, but what do you think of this decision of the FDA? Well, we have some advantages and some disadvantages in Europe. And our advantage is that my brute-neb was not withdrawn from the European market, so we can still work on that. The disadvantage is, in comparison to the US, you have at least two other VDKIs registered in Montesellen-Foma which are our color-bruitinib and Zano- bruitinib. But it's a bizarre situation because
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
